Skip to main content


You are here

Tokai Pharmaceuticals, Inc. Rings The Nasdaq Stock Market Opening Bell

Tuesday, November 18, 2014

Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, visited the Nasdaq MarketSite in Times Square on Monday, November 17. In honor of the occasion, Jodie Morrison, Chief Executive Officer, rang the Opening Bell.

Tokai went public in September 2014. The company’s lead drug candidate, galeterone, is a highly selective, multi-targeted, oral small molecule drug candidate for the treatment of prostate cancer. Galeterone was discovered by Angela Brodie, Ph.D. and Vincent Njar, Ph.D. at the University of Maryland, and is exclusively licensed by Tokai from UMB.